CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Göttingen
• Treatments: Alemtuzumab

Criteria

Inclusion Criteria:

• all risk groups in international prognostic index

• diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph node or by sufficiently extensive biopsy of an extranodal involvment, if there is no lymph node involvment.

• these lymphomas comprise: peripheral T-cell lymphoma PTCL-NOS Lennert´s lymphoma T-zone lymphoma angioimmunoblastic T-cell-lymphoma

• Performance status: ECOG (Eastern Cooperative Oncology Group Score) 0-3(Karnofsky index 40-100%)

• written consent of the patient

• Declaration of center participation

Exclusion Criteria:

• Already initiated lymphoma therapy(exept for the prephase treatment specified for this study)

• Serious accompanying disorder or impaired organ function

• bone marrow involvement>25%

• Known hypersensitivity to medications to be used

• Know HIV-positivity

• Active hepatitis infection, active CMV infection, prior florid tuberculosis

• floride systemic infections

• suspicion that patient compliance will be poor

• Simultaneous participation in any the study protocol

• prior chemo-or radiotherapy for malignancy

• other concomitant malignant disease

• Pregnancy or lactation period